Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.

Minnee P, Hessels D, Schalken JA, Van Criekinge W.

BMC Urol. 2019 Nov 29;19(1):124. doi: 10.1186/s12894-019-0561-6.

2.

Improving the barrier function of damaged cultured urothelium using chondroitin sulfate.

Rozenberg BB, Janssen DAW, Jansen CFJ, Schalken JA, Heesakkers JPFA.

Neurourol Urodyn. 2019 Nov 27. doi: 10.1002/nau.24240. [Epub ahead of print]

PMID:
31774209
3.

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.

van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Kroeze LI, Ligtenberg MJ, van Zon HB, Hendriksen Y, Keizer D, van de Stolpe A, Schalken JA, van Herpen CM.

Int J Cancer. 2019 Nov 19. doi: 10.1002/ijc.32795. [Epub ahead of print]

PMID:
31745978
4.

Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.

Boerrigter E, Groen LN, Van Erp NP, Verhaegh GW, Schalken JA.

Expert Rev Mol Diagn. 2019 Oct 11:1-12. doi: 10.1080/14737159.2019.1675515. [Epub ahead of print]

PMID:
31577907
5.

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.

van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group.

Eur J Cancer. 2019 Mar;110:62-70. doi: 10.1016/j.ejca.2018.12.035. Epub 2019 Feb 13.

PMID:
30771738
6.

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.

Luna Velez MV, Verhaegh GW, Smit F, Sedelaar JPM, Schalken JA.

Oncogene. 2019 May;38(19):3696-3709. doi: 10.1038/s41388-019-0696-7. Epub 2019 Jan 21.

7.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
8.

The importance of targeting intracrinology in prostate cancer management.

Hamid ARAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, Verhaegh G, Schalken JA.

World J Urol. 2019 May;37(5):751-757. doi: 10.1007/s00345-018-2529-7. Epub 2018 Oct 22. Review.

PMID:
30350016
9.

Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.

Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20.

PMID:
30127462
10.

Urine cell-based DNA methylation classifier for monitoring bladder cancer.

van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, Geavlete B, Moldoveanud C, Ene C, Dinney CP, Czerniak B, Schalken JA, Kiemeney LALM, Ribal MJ, Witjes JA, Alcaraz A.

Clin Epigenetics. 2018 May 30;10:71. doi: 10.1186/s13148-018-0496-x. eCollection 2018.

11.

Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.

Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, Burger DM, van Erp NP.

Ther Drug Monit. 2018 Apr;40(2):222-229. doi: 10.1097/FTD.0000000000000484.

12.

Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.

Hendriks RJ, Dijkstra S, Smit FP, Vandersmissen J, Van de Voorde H, Mulders PFA, van Oort IM, Van Criekinge W, Schalken JA.

Prostate. 2018 Apr;78(5):336-342. doi: 10.1002/pros.23477. Epub 2018 Jan 12.

13.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
14.

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.

Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA.

Oncotarget. 2017 Feb 7;8(31):50804-50813. doi: 10.18632/oncotarget.15133. eCollection 2017 Aug 1.

15.

A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.

Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa CA, Schalken JA, Mulders PFA, van Oort IM.

Prostate. 2017 Oct;77(14):1401-1407. doi: 10.1002/pros.23401. Epub 2017 Aug 29.

PMID:
28853167
16.

Molecular biomarkers to guide precision medicine in localized prostate cancer.

Smits M, Mehra N, Sedelaar M, Gerritsen W, Schalken JA.

Expert Rev Mol Diagn. 2017 Aug;17(8):791-804. doi: 10.1080/14737159.2017.1345627. Review.

PMID:
28635333
17.

Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations.

Ceder JA, Aalders TW, Schalken JA.

Stem Cell Res Ther. 2017 Apr 26;8(1):95. doi: 10.1186/s13287-017-0544-z.

18.

Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.

Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, Grutters JPC, Sedelaar JPM, van Oort IM.

BJU Int. 2017 Nov;120(5):659-665. doi: 10.1111/bju.13861. Epub 2017 Apr 29.

19.

Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.

Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP.

Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3986. Epub 2017 May 16.

20.

miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting ADAM9 and TGFBR2.

van Kampen JGM, van Hooij O, Jansen CF, Smit FP, van Noort PI, Schultz I, Schaapveld RQJ, Schalken JA, Verhaegh GW.

Cancer Res. 2017 Apr 15;77(8):2008-2017. doi: 10.1158/0008-5472.CAN-16-2609. Epub 2017 Feb 16.

21.

A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate.

Kok DE, Kiemeney LA, Verhaegh GW, Schalken JA, van Lin EN, Sedelaar JP, Witjes JA, Hulsbergen-van de Kaa CA, van 't Veer P, Kampman E, Afman LA.

Oncotarget. 2017 Feb 7;8(6):10565-10579. doi: 10.18632/oncotarget.14551.

22.

Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.

Hendriks RJ, van Oort IM, Schalken JA.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. doi: 10.1038/pcan.2016.59. Epub 2016 Dec 6. Review.

PMID:
27922627
23.

Urothelium update: how the bladder mucosa measures bladder filling.

Janssen DAW, Schalken JA, Heesakkers JPFA.

Acta Physiol (Oxf). 2017 Jun;220(2):201-217. doi: 10.1111/apha.12824. Epub 2016 Dec 14. Review.

PMID:
27804256
24.

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide.

Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP.

Clin Pharmacokinet. 2016 Nov;55(11):1369-1380. Review.

25.

TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse.

Janssen DA, Hoenderop JG, Heesakkers JP, Schalken JA.

Pflugers Arch. 2016 Oct;468(10):1741-9. doi: 10.1007/s00424-016-1859-9. Epub 2016 Aug 5.

26.

Major milestones in translational oncology.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA.

BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y.

27.

XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice.

Semenchenko K, Wasylyk C, Cheung H, Tourrette Y, Maas P, Schalken JA, van der Pluijm G, Wasylyk B.

PLoS One. 2016 Jul 18;11(7):e0159531. doi: 10.1371/journal.pone.0159531. eCollection 2016.

28.

A five-gene expression signature to predict progression in T1G3 bladder cancer.

van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA.

Eur J Cancer. 2016 Sep;64:127-36. doi: 10.1016/j.ejca.2016.06.003. Epub 2016 Jul 11.

PMID:
27414486
29.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2016 May 2. pii: mdw180. [Epub ahead of print] No abstract available.

PMID:
27141017
30.

TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier.

Janssen DA, Jansen CJ, Hafmans TG, Verhaegh GW, Hoenderop JG, Heesakkers JP, Schalken JA.

Acta Physiol (Oxf). 2016 Sep;218(1):38-48. doi: 10.1111/apha.12701. Epub 2016 May 25.

PMID:
27124500
31.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
32.

Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.

Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, van Oort IM, Mulders PF, Schalken JA.

Clin Chem Lab Med. 2016 Mar;54(3):483-92. doi: 10.1515/cclm-2015-0599.

PMID:
26630694
33.

Contemporary approaches to prostate cancer management.

Schalken JA, Westcott G.

Future Oncol. 2015;11(20):2735-6. doi: 10.2217/fon.15.238. No abstract available.

34.

The role of HOXC6 in prostate cancer development.

Hamid AR, Hoogland AM, Smit F, Jannink S, van Rijt-van de Westerlo C, Jansen CF, van Leenders GJ, Verhaegh GW, Schalken JA.

Prostate. 2015 Dec;75(16):1868-76. doi: 10.1002/pros.23065. Epub 2015 Aug 27.

PMID:
26310814
35.

Direct dynamic measurement of intracellular and extracellular lactate in small-volume cell suspensions with (13)C hyperpolarised NMR.

Breukels V, Jansen KC, van Heijster FH, Capozzi A, van Bentum PJ, Schalken JA, Comment A, Scheenen TW.

NMR Biomed. 2015 Aug;28(8):1040-8. doi: 10.1002/nbm.3341. Epub 2015 Jun 30.

PMID:
26123400
36.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2015 Aug;26(8):1589-604. doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3.

37.

The need for a personalized approach for prostate cancer management.

Sedelaar JP, Schalken JA.

BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.

38.

Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.

Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA.

Clin Cancer Res. 2015 Jul 1;21(13):3061-70. doi: 10.1158/1078-0432.CCR-14-3334. Epub 2015 Mar 18.

39.

The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.

Cremers RG, Eeles RA, Bancroft EK, Ringelberg-Borsboom J, Vasen HF, Van Asperen CJ; IMPACT Steering Committee, Schalken JA, Verhaegh GW, Kiemeney LA.

Urol Oncol. 2015 May;33(5):202.e19-28. doi: 10.1016/j.urolonc.2015.01.018. Epub 2015 Mar 5.

40.

Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: implications in development and cancer.

Bringuier PP, Schalken JA, Hervieu V, Giroldi LA.

Mech Dev. 2015 May;136:64-72. doi: 10.1016/j.mod.2015.02.001. Epub 2015 Feb 14.

41.

Noncoding RNAs as novel biomarkers in prostate cancer.

Rönnau CG, Verhaegh GW, Luna-Velez MV, Schalken JA.

Biomed Res Int. 2014;2014:591703. doi: 10.1155/2014/591703. Epub 2014 Aug 28. Review.

42.

Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.

Hamid AR, Verhaegh GW, Smit FP, van Rijt-van de Westerlo C, Armandari I, Brandt A, Sweep FC, Sedelaar JP, Schalken JA.

J Urol. 2015 Mar;193(3):1023-9. doi: 10.1016/j.juro.2014.09.021. Epub 2014 Sep 19.

PMID:
25242390
43.

KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.

Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, Schalken JA.

Prostate. 2014 Sep;74(12):1222-30. doi: 10.1002/pros.22839. Epub 2014 Jul 7.

PMID:
25043536
44.

Self-reported acne is not associated with prostate cancer.

Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, van de Kerkhof PC, Schalken JA, Kiemeney LA.

Urol Oncol. 2014 Oct;32(7):941-5. doi: 10.1016/j.urolonc.2014.02.019. Epub 2014 Jul 8.

PMID:
25011577
45.

Alterations of the myovesical plexus of the human overactive detrusor.

Kuijpers KA, Heesakkers JP, Schalken JA.

Biomed Res Int. 2014;2014:754596. doi: 10.1155/2014/754596. Epub 2014 Apr 15.

46.

Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A; Triptocare Study Group.

BJU Int. 2014 Oct;114(4):608-16. doi: 10.1111/bju.12542. Epub 2014 Apr 4.

47.

An update of the interstitial cell compartment in the normal human bladder.

Kuijpers KA, Heesakkers JP, Hafmans TG, Schalken JA.

Biomed Res Int. 2014;2014:464217. doi: 10.1155/2014/464217. Epub 2014 Feb 27.

48.

Prostate cancer biomarker profiles in urinary sediments and exosomes.

Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA.

J Urol. 2014 Apr;191(4):1132-8. doi: 10.1016/j.juro.2013.11.001. Epub 2013 Nov 7.

PMID:
24211598
49.

Clinical use of novel urine and blood based prostate cancer biomarkers: a review.

Dijkstra S, Mulders PF, Schalken JA.

Clin Biochem. 2014 Jul;47(10-11):889-96. doi: 10.1016/j.clinbiochem.2013.10.023. Epub 2013 Oct 29. Review.

PMID:
24177197
50.

Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI.

Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF.

Int J Mol Sci. 2013 May 28;14(6):11347-55. doi: 10.3390/ijms140611347.

Supplemental Content

Loading ...
Support Center